These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 16336514)

  • 1. Long QT syndrome: reduced repolarization reserve and the genetic link.
    Roden DM
    J Intern Med; 2006 Jan; 259(1):59-69. PubMed ID: 16336514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced long QT and torsade de pointes: recent advances.
    Kannankeril PJ; Roden DM
    Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation.
    Kirchhof P; Franz MR; Bardai A; Wilde AM
    J Am Coll Cardiol; 2009 Jul; 54(2):143-9. PubMed ID: 19573731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced q-T prolongation.
    Kao LW; Furbee RB
    Med Clin North Am; 2005 Nov; 89(6):1125-44, x. PubMed ID: 16227057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dangerous and life-threatening drugs - practical lessons from the long QT syndrome.
    Schutte D; Obel W
    Cardiovasc J S Afr; 2002; 13(2):54-61. PubMed ID: 11981581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long QT syndrome caused by noncardiac drugs.
    Viskin S; Justo D; Halkin A; Zeltser D
    Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital and acquired long QT syndromes.
    Walker BD; Krahn AD; Klein GJ; Skanes AC; Wang J; Hegele RA; Yee R
    Can J Cardiol; 2003 Jan; 19(1):76-87. PubMed ID: 12571698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
    Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
    Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.
    Zeltser D; Justo D; Halkin A; Prokhorov V; Heller K; Viskin S
    Medicine (Baltimore); 2003 Jul; 82(4):282-90. PubMed ID: 12861106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
    Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
    Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proarrhythmic (torsadogenic) effects of QT-prolonging non-antiarrhythmic drugs].
    Fazekas T; Liszkai G
    Orv Hetil; 2005 Mar; 146(10):451-60. PubMed ID: 15835343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of high-risk use of QT-prolonging medications.
    Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Extension of QT interval as a consequence of risk factor accumulation--case study].
    Sisáková M; Toman O; Floriánová A; Kadlecová J; Chroust K; Papousek I; Spinar J
    Vnitr Lek; 2006 Mar; 52(3):271-3. PubMed ID: 16722159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of increased short-term variability of QT interval to congenital long-QT syndrome.
    Hinterseer M; Beckmann BM; Thomsen MB; Pfeufer A; Dalla Pozza R; Loeff M; Netz H; Steinbeck G; Vos MA; Kääb S
    Am J Cardiol; 2009 May; 103(9):1244-8. PubMed ID: 19406266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long QT syndrome induced by cordaron and quinidine].
    Mironchik EV; Dolgosheĭ TS; Liskovich TG; Madeshkina GA; Kokhkovski AB; Tyshchenko AD
    Klin Med (Mosk); 2007; 85(3):69-71. PubMed ID: 17523411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.